Q1 Earnings Estimate for XFOR Issued By Brookline Cap M

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Stock analysts at Brookline Cap M issued their Q1 2026 earnings per share (EPS) estimates for X4 Pharmaceuticals in a report released on Tuesday, March 17th. Brookline Cap M analyst L. Cann expects that the company will post earnings of ($0.20) per share for the quarter. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. Brookline Cap M also issued estimates for X4 Pharmaceuticals’ Q2 2026 earnings at ($0.23) EPS and FY2030 earnings at $2.85 EPS.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Tuesday, March 24th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.14. X4 Pharmaceuticals had a negative return on equity of 115.27% and a negative net margin of 225.55%.The business had revenue of $2.57 million for the quarter, compared to analyst estimates of $1.68 million.

Other equities analysts also recently issued research reports about the stock. Guggenheim initiated coverage on shares of X4 Pharmaceuticals in a research note on Monday, March 9th. They set a “buy” rating and a $12.00 price objective on the stock. Stifel Nicolaus set a $10.00 price objective on X4 Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, December 5th. Wall Street Zen lowered X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, November 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research report on Monday, December 29th. Finally, Zacks Research downgraded shares of X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 26th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $28.88.

X4 Pharmaceuticals Price Performance

NASDAQ:XFOR opened at $4.17 on Thursday. X4 Pharmaceuticals has a 12-month low of $1.35 and a 12-month high of $9.56. The firm has a market cap of $379.14 million, a price-to-earnings ratio of -0.96 and a beta of 0.43. The company’s 50-day moving average is $3.66 and its two-hundred day moving average is $3.62. The company has a current ratio of 10.16, a quick ratio of 5.48 and a debt-to-equity ratio of 0.41.

Institutional Trading of X4 Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Indivisible Partners acquired a new position in X4 Pharmaceuticals during the fourth quarter valued at approximately $40,000. Squarepoint Ops LLC acquired a new stake in shares of X4 Pharmaceuticals in the fourth quarter worth $50,000. Two Sigma Investments LP purchased a new position in shares of X4 Pharmaceuticals in the 3rd quarter valued at $47,000. Stifel Financial Corp purchased a new position in shares of X4 Pharmaceuticals in the 4th quarter valued at $82,000. Finally, Virtu Financial LLC acquired a new position in shares of X4 Pharmaceuticals during the 4th quarter valued at $90,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.